How Tirzepatide is Administered
Tirzepatide is given as a once-weekly subcutaneous (SC) injection, starting at 2.5 mg weekly and titrated up monthly by 2.5 mg increments to a maximum dose of 15 mg weekly. 1
Administration Details
Route and Frequency:
- Subcutaneous injection once weekly (half-life 116.7 hours)
- Can be administered at any time of day, with or without meals
- FDA-approved doses: 5 mg, 10 mg, and 15 mg weekly for both obesity (2023) and type 2 diabetes (2022) 1
Dosing Algorithm
Standard Titration Schedule:
- Start: 2.5 mg SC once weekly for 4 weeks
- Week 5: Increase to 5 mg SC once weekly for 4 weeks
- Week 9: Increase to 7.5 mg SC once weekly for 4 weeks
- Week 13: Increase to 10 mg SC once weekly for 4 weeks
- Week 17: Increase to 12.5 mg SC once weekly for 4 weeks
- Week 21: Increase to 15 mg SC once weekly (maximum dose) 2
The monthly dose escalation is essential - this slow titration minimizes gastrointestinal side effects, which are the most common adverse events and occur primarily during dose escalation 1.
Critical Practical Considerations
Starting at the lowest dose (2.5 mg) is mandatory to prevent clinically significant side effects. In clinical trials, over 80% of patients achieved the target dose with this protocolized titration 2.
If treatment is interrupted: Patients must restart at the low 2.5 mg dose and re-titrate upward to allow the body time to re-acclimate to the medication 1.
Dose adjustments based on tolerability: If gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) limit tolerability, dose reduction or slower titration can be considered. However, the minimally effective dose for clinical benefit is currently unknown 2.
Renal Dosing
No dosage adjustments are required for renal impairment - tirzepatide can be used across all levels of kidney function without dose modification 3.
Common Pitfalls to Avoid
- Never skip the initial 2.5 mg starting dose - this is not a therapeutic dose but a necessary tolerance-building step
- Do not accelerate titration beyond monthly intervals, as this increases gastrointestinal adverse events
- Monitor for dehydration in patients with vomiting or diarrhea, as this can lead to renal impairment 1
- Counsel patients on dietary modifications during dose escalation: avoid fatty foods, don't eat past fullness, eat smaller portions more frequently 1
The subcutaneous injection formulation allows for convenient once-weekly dosing, which has demonstrated superior adherence compared to daily medications in obesity management.